Citation:Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, et al 2014

Citation

Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014 Apr;146(4):941-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24361468.

Critical appraisals

• Assign a critical appraisal

Cited by

1. 11.1 Epidemiology of keratinocyte cancers in immunosuppressed patients